Abstract. Human ether-à-go-go-related gene (hERG) potassium channels conduct the rapid component of the delayed rectifier potassium current (I Kr ), which is crucial for repolarization of cardiac action potential. Patients with hERG-associated long QT syndrome usually develop tachyarrhythmias during physical and/or emotional stress, both known to stimulate adrenergic receptors. The present study aimed to investigate a putative functional link between β 1 -adrenergic stimulation and I Kr in guinea-pig left ventricular myocytes and to analyze how I Kr is regulated following activation of the β 1 -adrenergic signaling pathway. The I Kr current was measured using a whole-cell patch-clamp technique. A selective β 1 -adrenergic receptor agonist, xamoterol, at concentrations of 0.01-100 µM decreased I Kr in a concentration-dependent manner. The 10 µM xamoterol-induced inhibition of I Kr was attenuated by the protein kinase A (PKA) inhibitor KT5720, the protein kinase C (PKC) inhibitor chelerythrine, and the phospholipase (PLC) inhibitor U73122, indicating involvement of PKA, PKC and PLC in β 1 -adrenergic inhibition of I Kr . The results of the present study indicate an association between I Kr and the β 1 -adrenergic receptor in arrhythmogenesis, involving the activation of PKA, PKC and PLC.
Introduction
Repolarization of the cardiac action potential is accomplished by several types of potassium currents. One of these, the rapid component of delayed rectifier potassium current (I Kr ), is unique in its ability to modify membrane repolarization at the end of each cardiac action potential (1) . Activation of I Kr , which is predominantly carried through the human ether-à-go-go-related gene (hERG) potassium ion channels, initiates membrane repolarization and terminates the plateau phase of the cardiac action potential (2) . Mutation in hERG or pharmacological blockade of the hERG channels can produce an excessive prolongation of the action potential duration and the QT interval, leading to proarrhythmic events usually characterized by polymorphic ventricular tachycardia or torsades de pointes (3) (4) (5) (6) (7) (8) (9) . Such cardiac electrical disturbances are often closely correlated with physical or emotional stress, particularly in patients with hereditary long QT syndrome, indicating a potential correlation between adrenergic stimulation and hERG potassium channel activity (10) .
Previous studies have revealed that hERG/I Kr currents are modulated by α-and β-adrenergic stimulation, thus providing a pathophysiological rationale for an increased incidence of arrhythmias during stress (11) (12) (13) (14) . In human hearts, there are several main subfamilies of the adrenergic receptor (adrenoceptor) family, namely α 1 -, α 2 -, β 1 -, β 2 -and β 3 -adrenoceptors. Our previous study found that I Kr currents in the guinea-pig left ventricular myocytes was regulated by α 1 -adrenergic stimulation via protein kinase C (PKC)-and protein kinase A (PKA)-dependent pathways (15) .
The β 1 -and β 2 -adrenoceptors are the predominant subtypes in the heart. In human myocardium, β 1 -adrenoceptors constitute 70-80% of the total β-adrenoceptors abundance (16) and an altered β 1 -adrenoceptor activity and/or signaling are associated with a high incidence of cardiac arrhythmias (17) . β 1 -adrenoceptor coupled with Gs-protein stimulates adenylate cyclase (AC), resulting in the accumulation of cyclic adenosine monophosphate (AMP) and the activation of PKA. The activation of the AC/cAMP/PKA pathway results in a complex regulation of hERG/I Kr . However, whether PKC and PLC are involved in β 1 -adrenoceptor-induced regulation of I Kr remains unclear. The present study aimed to investigate how I Kr is regulated in guinea-pig cardiomyocytes following activation of β 1 -adrenergic receptors, and the involvement of activation of PKA, PKC and PLC. CaCl 2 , 1.4 mmol l -1 MgSO 4 and 10 mmol l -1 HEPES; pH adjusted to 7.4 with 10 M NaOH. Calcium currents were blocked by 10 µM nifedipine in the bath solution and 10 µM chromanol 293B was used to ablate the slow component of the delayed rectifier potassium currents (I Ks ). Na 2 -ATP, EGTA, nifedipine, chromanol 293B, chelerythrine, U73122 and xamoterol were purchased from Sigma (Sigma-Aldrich, St. Louis, MO, USA), collagenase II from Worthington (Lakewood, NJ, USA) and KT5720 from Merck (Darmstadt, Germany). Dofetilide, a specific blocker of I Kr or hERG, was provided by Pfizer (Shanghai, China). All the other reagents were purchased from Amresco (Solon, OH, USA).
Materials and methods

Animal
For stock solutions, dofetilide was dissolved in distilled water to a concentration of 10 mM; KT5720, chelerythrine and U73122 were dissolved in dimethylsulfoxide (DMSO) to a concentration of 2.5 mM, 1 mM and 0.1 mM. These chemicals were stored at -20˚C until further use. The final concentration of DMSO was <0.5% in the bath solution and exerted no effect on the currents that were observed.
Quantification and statistics.
Following initiation of the test pulse, tail currents were measured. Changes in the current amplitude were normalized prior to the application of xamoterol. All the data were acquired by Pulse + Pulsefit V8.53 (HEKA Elektronik, Lambrecht, Germany) and were analyzed by SPSS 18.0 software (SPSS Inc., Chicago, IL, USA). Statistical data were presented as the mean ± standard error of the mean. A paired-sample t-test was used for determining significant differences prior to and following the xamoterol intervention. One-way analysis of variance, with a post hoc comparison using a Newman-Keuls test was performed to compare the differences among groups. P<0.05 was considered to indicate a statistically significant difference.
Results
Effects of xamoterol on I Kr tail currents.
A representative I Kr tail current from a guinea-pig ventricular myocyte is shown in Fig. 1A . In Fig. 1B , the current was completely blocked by 1 µM dofetilide, a specific inhibitor of I Kr , indicating lack of contribution from any other current to the tail current in the experimental settings of the present study. The dose-dependent effects of xamoterol, a specific β 1 -adrenoceptor agonist, on I Kr current amplitude were examined in freshly isolated guinea-pig ventricular myocytes. Fig. 2A shows a representative current trace when the cardiomyocyte was treated with by 0.01 µM-100 µM xamoterol. Fig. 2B shows the concentration-dependent reduction of I Kr elicited by xamoterol in cardiomyocytes. In the cardiomyocytes examined (n=5), the bath application of 0.01, 0.1, 1, 10 and 100 µM xamoterol significantly reduced the I Kr current amplitude to 0.96±0.12, 0.86±0.13, 0.67±0.12, 0.59±0.10 and 0.55±0.11 respectively, compared with the basic amplitude. The concentration of 10 µM was selected for xamoterol for the rest of this study, since this concentration had almost decreased the current by the maximum degree. To examine whether the xamoterol-induced effect was β 1 -adrenoreceptor-mediated, the specific β 1 -adrenoceptor (Fig. 3) . These results indicate that I Kr is regulated by β 1 -adrenoceptors in guinea-pig cardiomyocytes.
Effects of PKA inhibitor on xamoterol-induced inhibition of I Kr . Cardiomyocytes were pretreated with 2.5 µM KT5720, a specific PKA inhibitor, for 1 h prior to the examination of the 10 µM xamoterol-elicited effect on I Kr . The I Kr tail current and the current density-voltage curve prior to and following administration of xamoterol in cells pretreated with KT5720 is shown in Fig. 4B . In the present study, the I Kr tail current density decreased from 0.74±0.09 to 0.64±0.08 pA/pF at +40 mV. However, 10 µM xamoterol was found to reduce the I Kr tail current density from 0.88±0.09 to 0.50±0.05 pA/pF at +40 mV in the presence of an empty bath solution (Fig. 4A) . In other words, the I Kr tail current amplitude was reduced to 0.87±0.03 subsequent to 10 µM xamoterol in the presence of KT5720 (the second column in Fig. 5) , which was significantly different from that in the absence of KT5720, 0.56±0.04 (the control group, the first column in Fig. 5 ). These data demonstrate that a xamoterol-induced decrease in I Kr was reversed by KT5720. 
Xamoterol-induced inhibition of I Kr is antagonized by the PKC inhibitor chelerythrine and the PLC inhibitor U73122.
The guinea-pig left ventricular myocytes were pretreated with the 1 µM specific PKC inhibitor chelerythrine or 100 nM PLC inhibitor U73122 for one hour, and then the I Kr tail currents prior to and following xamoterol administration were examined. Xamoterol reduced the I Kr tail current density from 0.62±0.07 to 0.44±0.05 pA/pF at +40 mV (Fig. 4C) , and it decreased I Kr to 0.71±0.01 pA/pF in the presence of chelerythrine (Fig. 5) , which was significantly different from that in the absence of chelerythrine, the control group, 0.56±0.04 pA/pF (Fig. 5) . The current trace and the tail current density-voltage (Id-V) curve almost superimposed prior to and following xamoterol treatment in the presence of U73122 (Fig. 4D) , from 0.92±0.09 to 0.82±0.07 pA/pF at +40 mV, indicating that xamoterol failed to suppress I Kr when myocytes were pretreated with the PLC inhibitor. However, the effects of xamoterol were significantly different between the control and the U73122 group (Fig. 5) .
Discussion
The present study indicated that xamoterol inhibits I Kr through β-adrenoceptors in freshly isolated guinea-pig cardiomyocytes. Furthermore, this inhibitory effect was significantly attenuated by the PKA inhibitor KT5720, the PLC inhibitor U73122 and the PKC inhibitor chelerythrine. These data indicated the involvement of PKA, PKC and PLC activation in the β1-adrenoceptor-induced inhibition of the I Kr current.
Activation of β 1 -adrenoceptors has been demonstrated to elicit an inhibitory effect on I Kr or hERG via a cAMP/PKA-dependent pathway (11, 19) consistent with our data that the PKA inhibitor KT5720 attenuated the inhibitory effect of xamoterol. However, in an early report by Heath and Terrar (20) , a concentration-independent increase of the I Kr currents was observed at low concentrations of the β 1 -adrenergic agonist isoprenaline and the stimulatory effect of isoprenaline on I Kr was inhibited by the selective PKC inhibitor bisindolylmaleimide I. There may be several reasons for the disparate findings between the two laboratories, including differences in patch-clamp modes and experimental conditions, aswell as dual regulation of hERG by cAMP and PKA phosphorylation (21, 22) . Nonetheless, to the best of our knowledge the involvement of PKC in β 1 -adrenergic regulation of I Kr demonstrated in the present study has not been documented previously.
PKC is an important member of the signaling transduction pathway, capable of reducing hERG currents through a mechanism independent of PKC-elicited phosphorylation of hERG (23, 24) . The results of the present study indicated that xamoterol-induced inhibition of I Kr is partially modulated by PKC. In addition, the decrease in I Kr induced by xamoterol was also antagonized by the selective PLC inhibitor U73122. Usually PLC is linked to α 1 -adrenergic stimulation leading to the PIP 2 hydrolysis and then the activation of PKC. PIP 2 depletion has been shown to alter the cardiac I Kr current (25, 26) . PKC has also been shown to reduce the hERG current (27) . Although PKC and PLC are associated with the classical α 1 -adrenergic signaling pathway, the results of the present study reveal that PKC and PLC are also activated in the β 1 -adrenergic signaling pathway in the regulation of the I Kr /hERG currents, indicating that there may exist a 'cross-talk' between the α 1 -and β 1 -adrenergic signaling cascades. Therefore, our next aim is to analyze the details in this type of cross-talk and demonstrate direct evidence.
In conclusion, the present study demonstrates that I Kr is regulated by β 1 -adrenergic receptors in guinea-pig cardiomyocytes, via the PKA-, PKC-and/or PLC-dependent signaling pathways. These findings provide a possible correlation between stress and life-threatening arrhythmias and may provide insight into the pathogenesis and potential therapeutic strategies for clinical cardiac arrhythmias.
